Home » Stocks » TAK

Takeda Pharmaceutical Company Limited (TAK)

Stock Price: $16.84 USD -0.02 (-0.12%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 53.16B
Revenue (ttm) 29.36B
Net Income (ttm) 3.45B
Shares Out 3.15B
EPS (ttm) 1.08
PE Ratio 15.59
Forward PE 13.14
Dividend $180.00
Dividend Yield 1,068.88%
Trading Day July 26
Last Price $16.84
Previous Close $16.86
Change ($) -0.02
Change (%) -0.12%
Day's Open 16.77
Day's Range 16.69 - 16.85
Day's Volume 2,129,789
52-Week Range 14.97 - 19.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

XBIO stock is racing to the moon today, as Takeda Pharmaceuticals makes an announcement that will see higher demand for Xenetic products. The post XBIO Stock: Xenetic Soars on Takeda Expansion News appe...

Other stocks mentioned: XBIO
3 days ago - InvestorPlace

OSAKA, Japan--(BUSINESS WIRE)--Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders

6 days ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of Moderna's COVID-19 Vaccine & booster vaccine candidate in 2022.

Other stocks mentioned: MRNA
6 days ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from two final analyses from the Phase 3 HELP (Hereditary Angioedema Long-term...

2 weeks ago - Business Wire

ZURICH & BRUSSELS--(BUSINESS WIRE)--The European Federation of Crohn's and Ulcerative Colitis Associations (“EFCCA”) in collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) today announce...

2 weeks ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2...

3 weeks ago - Business Wire

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 350,000 shares of Takeda Pharmaceutical Co.

1 month ago - 24/7 Wall Street

DUBAI, UAE, June 16, 2021 /PRNewswire/ -- Takeda Pharmaceuticals Company (TSE: 4502) (NYSE: TAK) ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, headquartered in Japan, is cele...

1 month ago - PRNewsWire

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co.

1 month ago - 24/7 Wall Street

DUBAI, UAE, June 9, 2021 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) has introduced the "In Their Shoes"  platform, an award-winning, immersive simulation program to promote greater awareness and emp...

1 month ago - PRNewsWire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today at the American Transplant Congress (ATC) 2021 Virtual Connect presented results from a new subg...

1 month ago - Business Wire

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Other stocks mentioned: DBTX, EWTX, RXRX
1 month ago - GuruFocus

Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot's efficacy waned over time but that it was still “robust” in preventing hosp...

2 months ago - Benzinga

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that its dengue vaccine candidate (TAK-003) demonstrated continued ...

2 months ago - Business Wire

The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection. The application under priority review is seeking mariba...

2 months ago - Benzinga

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) h...

2 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under ...

2 months ago - Business Wire

Takeda Pharmaceuticals Inc. ( TAK , Financial) has cleared the decks and sees smoother sailing ahead. That's according to the Japanese company's CEO, Christophe Weber.

2 months ago - GuruFocus

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) ora...

2 months ago - Business Wire

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponat...

2 months ago - Business Wire

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...

Other stocks mentioned: CERC, CRSP, HZNP, JNJ, LLY, SDGR
2 months ago - InvestorPlace

Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and lower acquisition-related expenses. Takeda exceede...

2 months ago - Benzinga

Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc's COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.

Other stocks mentioned: MRNA
2 months ago - Reuters

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021). TAKEDA PRESI...

2 months ago - Business Wire

Takeda Pharmaceutical (TAK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

2 months ago - Zacks Investment Research

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE)...

2 months ago - Business Wire

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priori...

2 months ago - Business Wire

You might want to consider adding this company to your portfolio.

Other stocks mentioned: ARKG, JNJ, MRK, MRNA, NVAX, PFE
3 months ago - The Motley Fool

With the trading day about halfway over, the broad markets were pulling back after setting record highs to close out last week.

Other stocks mentioned: COUR, QCOM, CADE, DFS, EVRG, LSCC, TCOM
3 months ago - 24/7 Wall Street

Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into Longview Acquisition Corp. II (NYSE:LGV.U) according to GuruFocus' Real-Time Picks, a Premium feature.

Other stocks mentioned: BHC, CI, DXC, THC
3 months ago - GuruFocus

The company is taking back rights to one drug candidate and discontinuing development of another.

Other stocks mentioned: MTEM
3 months ago - The Motley Fool

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide upd...

3 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to O...

3 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer Healthcare Comp...

3 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has teamed up with BridGene Biosciences to discover small molecules against hard-to-drug therapeutic targets. The deal will utilize BridGene's IMTAC Chemoproteom...

3 months ago - Benzinga

Cathie Wood's Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain s...

Other stocks mentioned: AMZN, BABA, GOOG, GOOGL, PLTR
4 months ago - Benzinga

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company's...

4 months ago - Business Wire

Small-molecule mRNA translation Israeli firm Anima Biotech Inc has landed a new research deal with Takeda Pharmaceutical Co Ltd (NYSE: TAK), covering as many as six programs for genetically-defined neur...

4 months ago - Benzinga

Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into HighCape Capital Acquisition Corp. (NASDAQ:CAPA) according to GuruFocus' Real-Time Picks, a Premium feature.

Other stocks mentioned: BHC, CAPA, CI, DXC, THC
4 months ago - GuruFocus

Japan's Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's (NYSE: JNJ) single-dose COVID-19 vaccine....

4 months ago - Benzinga

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood a...

4 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufac...

4 months ago - Business Wire

OSAKA, Japan--(BUSINESS WIRE)--Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks

4 months ago - Business Wire

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Gr...

4 months ago - Business Wire

DEPTFORD, N.J.--(BUSINESS WIRE)--BioLife Plasma Services announces the opening of its first plasma donation center in New Jersey.

4 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has exercised the option to acquire Maverick Therapeutics, following an agreement signed in 2017, in which Takeda received an equity stake and an exclusive right...

Other stocks mentioned: TXAC
4 months ago - Benzinga

OSAKA, Japan & BRISBANE, Calif.--(BUSINESS WIRE)--Takeda exercised its option to acquire Maverick, expanding its immuno-oncology portfolio with two development candidates and a T-cell engager platform

4 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has asked regulators to approve the use of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (mRNA-1273 or TAK-919). Takeda filed the New Drug Application to import ...

Other stocks mentioned: MRNA
4 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces New Drug Application submitted to import and distribute Moderna's COVID-19 vaccine candidate in Japan.

Other stocks mentioned: MRNA
4 months ago - Business Wire

Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic en...

Other stocks mentioned: OVID
4 months ago - Benzinga

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1781
CEO
Christophe Weber
Employees
47,099
Stock Exchange
NYSE
Ticker Symbol
TAK
Full Company Profile

Financial Performance

In 2020, TAK's revenue was 3.20 trillion, a decrease of -2.84% compared to the previous year's 3.29 trillion. Earnings were 376.01 billion, an increase of 749.90%.

Financial numbers in millions JPY.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is 21.78, which is an increase of 29.33% from the latest price.

Price Target
$21.78
(29.33% upside)
Analyst Consensus: Buy